Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of olaparib maintenance monotherapy in BRCA wild-type advanced ovarian cancer after first-line platinum chemotherapy
2020-005960-68Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Olaparib maintenance monotherapy with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Jun 2021; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2020-005960-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005960-68.